Roche has launched a newborn screening test that checks for spinal muscular atrophy (SMA), severe combined immunodeficiency (SCID) and sickle cell disease (SCD) in a single assay. The LightMix Newborn TREC/SMN1/HBB kit was announced from Berlin on 30 September 2026 and is made by Roche TIB MOLBIOL. It is CE-marked for countries that accept the mark and is not available in the United States, according to the company press release.
Key Takeaways
- The new newborn screening test detects SMA, SCID and sickle cell disease together in one assay.
- It runs on LightCycler systems and is designed to fit into existing laboratory workflows.
- The kit carries a CE mark under the European in vitro diagnostic regulation (IVDR) and is not available in the US.
- Roche says early detection matters because these conditions can cause severe, lasting harm before symptoms appear.
- Performance data, pricing and country rollout details were not given in the announcement.
What Is the LightMix Newborn Screening Test?
The LightMix Newborn TREC/SMN1/HBB kit is a molecular diagnostic test for newborn screening laboratories. Its name lists the three targets it looks for: TREC, a marker used to flag SCID; SMN1, the gene whose deletion causes SMA; and HBB, the gene changed in sickle cell disease. Roche describes it as a ready-to-use solution that works on its existing LightCycler instruments.
Newborn screening programmes test large numbers of babies shortly after birth to find serious conditions before symptoms appear. Running three tests in one assay can reduce the number of separate steps a laboratory has to manage, which is the main practical selling point of the kit. The US Centers for Disease Control and Prevention explains how newborn screening works in the United States, where programmes are run by individual states.
Newborn Screening Test at a Glance
| Item | Detail |
|---|---|
| Product | LightMix Newborn TREC/SMN1/HBB kit |
| Maker | Roche TIB MOLBIOL |
| Detects | SMA, SCID and sickle cell disease in one assay |
| Instrument | LightCycler systems |
| Regulatory status | CE mark (IVDR); not available in the US |
| Announced | 30 September 2026, Berlin |
The Three Conditions Explained
Spinal muscular atrophy (SMA)
SMA is a genetic neuromuscular disease in which nerve cells in the spinal cord degenerate progressively. The announcement links it to homozygous deletions of exon 7 of the SMN1 gene and says early treatment can prevent severe nerve damage and permanent disability.
Severe combined immunodeficiency (SCID)
SCID is a rare, life-threatening inherited disorder in which a baby lacks functioning T cells, leaving the immune system unable to fight infection. Without intervention it is typically fatal in the first one to two years of life, and it can be treated with a bone marrow transplant when found early.
Sickle cell disease (SCD)
SCD is an inherited red blood cell disorder caused by a mutation in the HBB gene. Rigid, sickle-shaped cells can block blood vessels. Early care lowers the risk of severe infections and early death, and Fierce Biotech reports that preventive measures such as penicillin can sharply cut infant mortality when the disease is found early.
Why a Single Assay Matters
Marcus Droege, chief executive of TIB MOLBIOL, said: “When a baby is born with a condition like SMA or SCID, every single day counts. Catching these diseases before symptoms appear isn’t just about early diagnosis; it’s the difference between a child thriving or facing severe, lifelong disability.”
According to Fierce Biotech, competitors such as ViennaLabs offer individual tests for these conditions, while the Roche kit performs all three together. That is the product claim at the centre of the launch. It is a company claim, and laboratories will want their own validation data before changing methods.
Where Is the Test Available?
The kit is intended for countries that accept the CE mark, so its first market is Europe and other CE-mark regions. It is not available in the US. Roche did not list specific countries, and the announcement does not say whether any national screening programme has adopted the test.
What Is Not Yet Known
- Clinical performance: no sensitivity, specificity or false-positive figures were published in the announcement.
- Pricing and uptake: no price, customer or programme adoption was disclosed.
- Screening policy: national programmes decide which conditions to screen, so availability of a kit does not mean every baby will be tested for all three conditions.
What It Means: Our Assessment
In our assessment, the Roche newborn screening test is a practical efficiency step rather than a scientific breakthrough. Its impact depends on whether national and regional programmes add SMA, SCID and sickle cell disease to their panels, since many treatments for these conditions are time-sensitive. For laboratories already using LightCycler systems, a multiplex kit may be an easy upgrade.
The launch also reflects wider growth in genetic testing, from prenatal screening to consumer products, which we cover in our non-invasive prenatal testing market and direct-to-consumer genetic testing market reports. Readers following rare disease care may also want our analysis of the congenital hyperinsulinism treatment market.
Frequently Asked Questions
What does the Roche newborn screening test detect?
It detects spinal muscular atrophy, severe combined immunodeficiency and sickle cell disease in a single assay.
What is the kit called?
It is the LightMix Newborn TREC/SMN1/HBB kit, made by Roche TIB MOLBIOL.
Is it available in the United States?
No. The announcement says the test is not available in the US and is CE-marked for countries accepting that mark.
What instrument does it use?
It runs on Roche LightCycler systems.
Why is early detection important?
These conditions can cause severe, lasting harm or death before symptoms are obvious, and treatment is most effective when started early.
How we reported this: information comes from the company press release dated 30 September 2026 and trade coverage by Fierce Biotech. Claims about the kit are company-reported and not independently verified. Last updated 2 October 2026. This article is for information only and is not medical advice; speak to a clinician about screening for a specific child.
